Bladder cancers often start with just the superficial lining of the bladder. Early on they can be treated and cured by removal. If the cancer has spread to other parts of the body then it is usually not curable, although it can respond to available treatments. We do need to develop better treatments and this involves performing clinical trials.
Bladder cancer is occurs when abnormal cells grow and divide in an uncontrolled way. It is more common in people over 60 and in men than women.
This large-scale, randomised trial will determine the effects of adding
mitomycin to BCG on cure rates, survival, side effects, and quality of life.
The Urothelial transitional cell cancer (uTCC) typically starts in the cells that line the inside of the urinary system. This study looks at whether Nab-Paclitaxel improves survival and is less toxic with improved quality of life compared with Paclitaxel.
This trial is aimed at managing bladder cancer that has spread into the wall of the bladder, to assess the addition of an additional new drug called pembrolizumab to the standard therapy of chemotherapy and radiation therapy.
This project follows on from Phase I, which involved qualitative research to develop a draft Non-Muscle Invasive Bladder Cancer Symptom Index (NMIBC-SI). The aim of the current project is to evaluate the psychometric properties of the NMIBC-SI.